Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Deal Watch: Mylan Shareholders Give Thumbs-Up To Perrigo Acquisition

Executive Summary

Medivation continues its pipeline expansion efforts beyond Xtandi by paying $410m up front for a Phase III PARP inhibitor from BioMarin. Novo Nordisk acquires a pair of diabetes-focused start-ups, while Immatics will establish a US subsidiary on the MD Anderson Cancer Center campus in Houston.

Advertisement

Related Content

Pfizer Will Retain Infliximab Biosimilar In US After Hospira Acquisition

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register